Researchers Inclined towards Developing Next-Generation Antibodies for Cancer Treatment

Release Date: 27-Nov-2020

Researchers are pointing towards the potential benefits of the antibodies that can target two epitopes (bispecific antibodies) so that the cancer patients could experience dual mechanisms of action and how next-generation immunotherapy drugs could drive the future of the cancer therapeutics market. It has been observed through hundreds of clinical research studies, that cancer cells have adopted hundreds of mechanisms through which they can escape the human immune response. Hundreds of researchers are now pointing towards revolutionizing the entire cancer therapeutics market by the advent of immunotherapies such as monoclonal antibodies.

In hundreds of pharmaceutical markets, several checkpoint inhibitors such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) against different cancer indications are aiming at dominating the entire cancer therapeutics market. But it has been observed that in more than 60% of the patient population do not respond to the immune checkpoint therapies as they develop resistance against the mechanism of action of therapies. Therefore, to overcome such limitations in the entire cancer therapeutics market, researchers are now focused towards developing next-generation antibody oncology drugs. A prime example of such development in the cancer therapeutics world is to develop an antibody that could bind specifically to two different target proteins. As per the research conducted, a group of researchers are already on the urge of developing bispecific antibodies is TJ-CD4B/ ABL111. It is witnessed that the arrival of next-generation monoclonal antibody for the cancer patients will make the entire cancer therapeutics market accelerate at a very high rate.